IOL ChemicalsQ1 FY27
IOL Chemicals Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹172P/E: 28.2Market Cap: ₹5.0K CrSector: Pharmaceuticals & Biotechnology
Management growth scorecard
Revenue
Category 3
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- →FY27 revenue growth guidance: 15% to 20%
- →FY28 revenue growth plan: Approximately 15% to 20%
- →EBITDA margin for FY27 expected in range of 14% to 15%, with potential slight improvement in FY28 (15% to 17%)
- →Growth driven by better capacity utilization, improved product mix, operational efficiencies, and increased exports
- →Continued expansion in non-ibuprofen API portfolio to support broad-based growth
- →Targeting non-ibuprofen products to contribute around 50%-55% of API segment by FY29
- →Export contribution expected to be around 25% to 30% of revenue, targeting ~30% in near term
- →New capacities and backward integration projects underway but major expansions expected post FY27
- →Sustained growth visibility for the year with reasonable order book visibility and demand expected to remain strong
Margin guidance
Category 3- →FY27 Revenue Growth Guidance: 15% to 20% increase expected.
- →FY27 EBITDA Margin Guidance: Targeted range of 14% to 15%; Q1 margin at 14.6% suggests potential for sustaining or modestly improving margins.
- →FY28 Revenue Growth Plan: Anticipated 15% to 20% top-line growth.
- →FY28 EBITDA Margin Expectation: Around 15% to 17%, subject to prevailing market conditions.
- →Broad-based growth across API portfolio, with non-ibuprofen products expected to contribute approximately 50% to 55% of API revenue by FY29.
- →Export contribution projected around 25% to 30% of revenue, with potential to exceed 30%.
- →Growth driven by better capacity utilization, improved product mix, operational efficiencies, and increasing regulated market penetration.
- →No one-off gains expected; earnings growth supported by operational performance and strategic expansion.
3 more insights locked — sign up free to unlock
Fundraise plans
- →The transcript does not mention any current or planned fundraising through debt or equity.
- →The company discusses ongoing capex plans of INR 200-250 crores annually for growth and maintenance but does not specify the funding source.
- →There is no specific discussion about raising external capital via equity or debt during the calls.
- →Management focuses on operational efficiencies, capacity expansions, and internal cash flows to support growth.
- →Any future funding, if needed, is not elaborated upon in the provided transcript.
Order book
Yes- →The company has reasonable visibility into its order book for the coming quarter, providing confidence in the overall guidance for the year.
- →Strong demand and healthy order inflow are expected to sustain growth this year.
- →Export agreements include quantities with specific customers, and some variability quarter-to-quarter in dispatches can cause minor fluctuations in export numbers.
- →No specific quantitative details on the total order book size or pending orders were disclosed during the call.
- →Company maintains a disciplined approach to capital allocation and investments based on long-term returns, implying ongoing order inflow aligned with capacity expansions and product mix improvements.
Capex plans
Yes- →The company plans a capex of approximately INR 200-250 crores per year.
- →Around 60% of the annual capex is directed towards expansion and new product developments.
- →The remaining 40% of capex is for infrastructure improvements, enhancing efficiencies, and cost reduction.
- →The company has a 101-acre land parcel for future expansion; statutory permissions are underway.
- →New projects on the 101-acre land are expected beyond the current fiscal year (not in FY27).
- →R&D is active with ongoing projects; they will share more when proof-of-concepts are ready.
- →Investments in high-end analytical machines (XRD, LCMS, GCMS) have been made to support quality and impurity analysis.
- →Strategic focus on building a diversified API portfolio with backward integration and operational efficiencies.
How does IOL Chemicals rank vs peers in Pharmaceuticals & Biotechnology?
Pro feature1IOL Chemicals
Rev 3Mar 3
See full Pharmaceuticals & Biotechnology sector rankings
How does IOL Chemicals rank in Pharmaceuticals & Biotechnology?
Compare IOL Chemicals against every Pharmaceuticals & Biotechnology company (Q1 FY27) on revenue, margins and earnings-call signals.